Suppr超能文献

阿普唑仑治疗惊恐障碍:一项回顾性分析。

Alprazolam in panic disorder: a retrospective analysis.

作者信息

Shelton R C, Harvey D S, Stewart P M, Loosen P T

机构信息

Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN.

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 1993 May;17(3):423-34. doi: 10.1016/0278-5846(93)90076-5.

Abstract
  1. The charts of 78 panic disorder outpatients treated with alprazolam (mean dose 4.30 mg/day, mean duration 31.9 months) were reviewed for demographics, past history (including substance abuse and major depression), and evidence of alprazolam abuse. In addition, the patients were evaluated by Clinical Global Index for improvement at last contact. 2. Moderate to significant recovery was found in 77% of patients. Major depression was seen in 41%. Depressed patients were more likely to have coexisting agoraphobia and a past history of alcohol abuse than non-depressives. 3. There was no DSM-III-R anxiolytic abuse, but 12% showed unauthorized use of the alprazolam. These subjects were three times more likely to have a history of drug abuse than non-misusers. 4. These results indicate that alprazolam is effective in the long-term treatment of panic disorder, but that prolonged management may be required. Further, the data raise concerns about use in panic patients with substance abuse histories.
摘要
  1. 回顾了78例接受阿普唑仑治疗的惊恐障碍门诊患者的病历(平均剂量4.30毫克/天,平均疗程31.9个月),以了解其人口统计学信息、既往史(包括药物滥用和重度抑郁症)以及阿普唑仑滥用的证据。此外,在患者最后一次就诊时,通过临床综合指标对其改善情况进行评估。2. 77%的患者有中度至显著恢复。41%的患者患有重度抑郁症。与非抑郁症患者相比,抑郁症患者更易同时患有广场恐惧症和有酒精滥用史。3. 没有《精神疾病诊断与统计手册》第三版修订本(DSM-III-R)规定的抗焦虑药滥用情况,但12%的患者存在未经授权使用阿普唑仑的情况。这些患者有药物滥用史的可能性是非滥用者的三倍。4. 这些结果表明,阿普唑仑在惊恐障碍的长期治疗中有效,但可能需要长期管理。此外,这些数据引发了对有药物滥用史的惊恐障碍患者使用该药物的担忧。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验